Search
Bicycle Therapeutics PLC
BCYCAdd to Watchlist
3.610USD
+0.130+3.74%
Close 11-06 16:00（ET）
252.02MMarket Cap
LossP/E TTM
Bicycle Therapeutics PLC (BCYC) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Bicycle Therapeutics PLC in the past month.
Buy
3 Strong Buy
4 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
9.857USD+169.32%
BCYC Analyst Recommendation Trends
In the current month, BCYC has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BCYC average Analyst price target in the last month is 9.857.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
5
3
3
3
3
4
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
11
12
13
13
14
BCYC Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, BCYC EPS is projected to reach -0.438 in FY2026Q4, following reported EPS of -0.150 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.62
-0.58
-0.43
-0.44
-0.58
Actual
-0.87
-0.72
-0.15
--
--
Surprise
-40.58%
-25.28%
+65.42%
--
--
FAQs
What is Bicycle Therapeutics PLC's expected revenue for the next quarter?
Bicycle Therapeutics PLC's expected revenue is 1.82M.
What is Bicycle Therapeutics PLC's price target?
Analysts forecast that Bicycle Therapeutics PLC's price target is USD 9.86, with the highest forecast at USD 14.00 and the lowest forecast at USD 5.00.
How have Bicycle Therapeutics PLCBCYC's recent earnings per share performed?
The market expectation was USD -0.15, while Bicycle Therapeutics PLCBCYC's earnings per share (EPS) for the previous quarter was USD -0.72. EPS for the next quarter is expected at USD -0.44.
What is the analyst rating for Bicycle Therapeutics PLC?
Based on the ratings of Bicycle Therapeutics PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.